FDG PET coverage
This article was originally published in The Gray Sheet
Executive Summary
Jan. 28 1national coverage decision extends Medicare coverage to fluoro-d-glucose positron emission tomography (FDG PET) scans for the staging of pre-treatment metastases in newly diagnosed cervical cancer as an adjunct to conventional imaging. CMS also will cover clinical trials of FDG PET scans of cervical cancer if the study meets FDA criteria for a category B IDE exemption, or if the study is designed to provide information that assists patient management and is approved by CMS. The decision finalizes a Nov. 1 coverage proposal (2"The Gray Sheet" Nov. 8, 2004, p. 11)...